Martin Puchwein

Martin Puchwein is a highly accomplished professional with a passion for utilizing medical and digital innovations to enhance patient outcomes.

With a strong background in physics and executive education, having studied at prestigious institutions like ETH Zurich, Karl-Franzens-Universität Graz, and Harvard Business School, Martin brings a unique perspective to the intersection of science and business.

Throughout his career, Martin has held key leadership positions in renowned organizations such as Novartis and HEXAL AG/Sandoz Germany, where he led various strategic and operational initiatives across a diverse range of therapeutic areas.

His extensive experience includes serving as the Global Head Transplant at Novartis, Country President & General Manager Pharma at Novartis, Head Business Franchise Immunology & Dermatology at Novartis, and Head Oncology, Nephrology, and Transplant at HEXAL AG/Sandoz Germany.

Martin's exceptional track record in both small and large countries, as well as in global roles, underscores his versatility and proficiency in driving business growth and fostering a culture of excellence within teams.

Noteworthy contributions include his role as a former Board Member at the HST Chamber of Commerce Switzerland - Czech Republic, demonstrating his commitment to shaping the business landscape beyond traditional organizational boundaries.

Additionally, Martin has honed his strategic acumen through roles such as Director Global Strategic Planning at Sandoz Intl. and as a Project Leader at The Boston Consulting Group, further showcasing his ability to navigate complex business challenges with innovative solutions.

By focusing on creating a conducive work culture that empowers teams to perform at their best, Martin Puchwein exemplifies leadership characterized by vision, strategic thinking, and a relentless drive for transformative change in the healthcare industry.